Mobile Wearable Devices Show Some Sleep Disturbances During Multiple Myeloma Treatment
Younger patients had a significant decrease in sleep time on days they received dexamethasone.
Diagnosis & Disease Information
Expanding Medicaid Eligibility May Improve Survival in Patients With Cancer
Patients living in states with lower eligibility limits had worse survival rates, regardless of cancer stage at diagnosis.
Integrated Palliative Care Improves Symptoms, Coping in Patients Hospitalized for Acute Myeloid Leukemia Treatment
Analysis findings that demonstrated the benefit of an integrated palliative care intervention for hospitalized patients with AML were presented at the 2021 ASCO Annual Meeting.
Ivosidenib Plus Venetoclax, With or Without Azacitidine, Appears Effective in IDH1-Mutated Myeloid Malignancies
The 1-year overall survival rate was 71%.
FORTE Study Compares Multiple Regimens in Patients With Multiple Myeloma With Cytogenetic Abnormalities
Researchers sought to determine whether a combination carfilzomib-lenalidomide-dexamethasone induction and consolidation with ASCT would improve survival in patients with MM with cytogenetic abnormalities.
Combination Therapy Shows Promise in Patients With Ultra High-Risk Multiple Myeloma, PCL
Researchers sought to determine whether a combination therapy with bortezomib-augmented ASCT would have efficacy in patients with ultra high-risk multiple myeloma or plasma cell leukemia.
Daratumumab Maintenance Shows Clinical Benefit in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
Researchers sought to determine whether daratumumab maintenance therapy would be effective in patients with newly diagnosed multiple myeloma.
Carfilzomib-Based Consolidation Regimen May Be Inferior to ASCT in Patients With Multiple Myeloma
Researchers sought to determine whether carfilzomib-based consolidation and maintenance therapy regimen may yield similar outcomes to those seen with ASCT in patients with MM.
New C-CAR039 Therapy Is Safe and Effective in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Researchers sought to determine whether C-CAR039 would be safe and effective in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Acalabrutinib May Reduce Toxicity in Chronic Lymphocytic Leukemia Compared With Ibrutinib
Researchers sought to determine whether acalabrutinib may lower the rate of treatment-related AEs while maintaining a similar PFS in patients with CLL.
- Loading...
Loading...
Next post in ASCO 2021
Loading... 
Loading...